
CLAIMS


1. A compound of formula (I):






(I),

or a pharmaceutically acceptable salt thereof, wherein

 is a single or double bond;

 is selected from

, , and , wherein  indicates the point of attachment to the rest of the molecule;

W is O or CH_2;

X is O or CH_2;

R^1 and R^2 are each independently selected from H, C_{1-3}-alkyl, and halo;

R^3 is selected from H and C_{1-3}-alkyl;

R^4 is selected from H, C_{1-6}-alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6}-cycloalkyl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, phenyl, C_{3-6}-cycloalkyl-C_{1-3}-alkyl-, (4-10 membered heterocycloalkyl)-C_{1-3}-alkyl-, (5-10 membered heteroaryl)-C_{1-3}-alkyl-, phenyl-C_{1-3}-alkyl-, halo, CN, NO_2, OR^{4a}, SR^{4a}, $C(O)OR^{4a}$, $C(O)R^{4b}$, $C(O)NR^{4c}R^{4d}$, $C(O)NR^{4c}(OR^{4a})$, $C(O)NR^{4c}(S(O)_2R^{4b})$, $C(O)NR^{4c}(S(O)_2NR^{4c}R^{4d})$, $NR^{4c}OR^{4a}$, $NR^{4c}R^{4d}$, $NR^{4c}(C(O)R^{4b})$, $NR^{4c}(C(O)OR^{4a})$, $N(OR^{4a})(C(O)R^{4b})$, $NR^{4c}(C(O)NR^{4c}R^{4d})$, $NR^{4c}(C(O)NR^{4c}(C(O)R^{4b}))$, $NR^{4c}(S(O)_2R^{4b})$, $NR^{4c}(S(O)_2NR^{4c}R^{4d})$, $NR^{4c}(C(O)NR^{4c}(S(O)_2R^{4b}))$, $OC(O)R^{4b}$, $OC(O)NR^{4c}R^{4d}$, $ONR^{4c}(C(O)R^{4b})$, $OS(O)_2R^{4b}$, $OP(O)(OR^{4e})(OR^{4f})$, $S(O)OR^{4a}$, $S(O)R^{4b}$, $S(O)_2R^{4b}$, $S(O)_2NR^{4c}R^{4d}$, $S(O)_2OR^{4a}$, $S(=NR^{4g})(O)R^{4b}$, $S(=NR^{4g})(O)NR^{4c}NR^{4d}$, $P(O)(OR^{4e})(OR^{4f})$, and $P(O)(OR^{4e})(R^{4f})$, wherein the C_{1-6}-alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6}-cycloalkyl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, phenyl, C_{3-6}-cycloalkyl-C_{1-3}-alkyl-, (4-10 membered heterocycloalkyl)-C_{1-3}-alkyl-, (5-10 membered heteroaryl)-C_{1-3}-alkyl-, and phenyl-C_{1-3}-alkyl- of R^4 are each optionally substituted with 1, 2, or 3 groups independently selected from C_{1-3} alkyl, halo, CN, NO_2, OR^{4A}, SR^{4A}, $C(O)OR^{4A}$,

$C(O)R^{4B}$, $C(O)NR^{4C}R^{4D}$, $C(O)NR^{4C}(OR^{4A})$, $C(O)NR^{4C}(S(O)_2R^{4B})$, $C(O)NR^{4C}(S(O)_2NR^{4C}R^{4D})$, $NR^{4C}OR^{4A}$, $NR^{4C}R^{4D}$, $NR^{4C}(C(O)R^{4B})$, $NR^{4C}(C(O)OR^{4A})$, $N(OR^{4A})(C(O)R^{4B})$, $NR^{4C}(C(O)NR^{4C}R^{4D})$, $NR^{4C}(C(O)NR^{4C}(C(O)R^{4B}))$, $NR^{4C}(S(O)_2R^{4B})$, $NR^{4C}(S(O)_2NR^{4C}R^{4D})$, $NR^{4C}(C(O)NR^{4C}(S(O)_2R^{4B}))$, $OC(O)R^{4B}$, $OC(O)NR^{4C}R^{4D}$, $ONR^{4C}(C(O)R^{4B})$, $OS(O)_2R^{4B}$, $OP(O)(OR^{4E})(OR^{4F})$, $S(O)OR^{4A}$, $S(O)R^{4B}$, $S(O)_2R^{4B}$, $S(O)_2NR^{4C}R^{4D}$, $S(O)_2OR^{4A}$, $S(=NR^{4G})(O)R^{4B}$, $S(=NR^{4G})(O)NR^{4C}NR^{4D}$, $P(O)(OR^{4E})(OR^{4F})$, and $P(O)(OR^{4E})(R^{4F})$;

R^5 is selected from H, C_{1-6}-alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6}-cycloalkyl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, phenyl, C_{3-6}-cycloalkyl-C_{1-3}-alkyl, (4-10 membered heterocycloalkyl)-C_{1-3}-alkyl-, (5-10 membered heteroaryl)-C_{1-3}-alkyl-, phenyl-C_{1-3}-alkyl-, halo, CN, NO_2, OR^{5a}, SR^{5a}, $C(O)OR^{5a}$, $C(O)R^{5b}$, $C(O)NR^{5c}R^{5d}$, $C(O)NR^{5c}(OR^{5a})$, $C(O)NR^{5c}(S(O)_2R^{5b})$, $C(O)NR^{5c}(S(O)_2NR^{5c}R^{5d})$, $NR^{5c}OR^{5a}$, $NR^{5c}R^{5d}$, $NR^{5c}(C(O)R^{5b})$, $NR^{5c}(C(O)OR^{5a})$, $N(OR^{5a})(C(O)R^{5b})$, $NR^{5c}(C(O)NR^{5c}R^{5d})$, $NR^{5c}(C(O)NR^{5c}(C(O)R^{5b}))$, $NR^{5c}(S(O)_2R^{5b})$, $NR^{5c}(S(O)_2NR^{5c}R^{5d})$, $NR^{5c}(C(O)NR^{5c}(S(O)_2R^{5b}))$, $OC(O)R^{5b}$, $OC(O)NR^{5c}R^{5d}$, $ONR^{5c}(C(O)R^{5b})$, $OS(O)_2R^{5b}$, $OP(O)(OR^{5e})(OR^{5f})$, $S(O)OR^{5a}$, $S(O)R^{5b}$, $S(O)_2R^{5b}$, $S(O)_2NR^{5c}R^{5d}$, $S(O)_2OR^{5a}$, $S(=NR^{5g})(O)R^{5b}$, $S(=NR^{5g})(O)NR^{5c}NR^{5d}$, $P(O)(OR^{5e})(OR^{5f})$, and $P(O)(OR^{5e})(R^{5f})$, wherein the C_{1-6}-alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6}-cycloalkyl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, phenyl, C_{3-6}-cycloalkyl-C_{1-3}-alkyl-, (4-10 membered heterocycloalkyl)-C_{1-3}-alkyl-, (5-10 membered heteroaryl)-C_{1-3}-alkyl-, and phenyl-C_{1-3}-alkyl- of R^5 are each optionally substituted with 1, 2, or 3 groups independently selected from C_{1-3} alkyl, halo, CN, NO_2, OR^{5A}, SR^{5A}, $C(O)OR^{5A}$, $C(O)R^{5B}$, $C(O)NR^{5C}R^{5D}$, $C(O)NR^{5C}(OR^{5A})$, $C(O)NR^{5C}(S(O)_2R^{5B})$, $C(O)NR^{5C}(S(O)_2NR^{5C}R^{5D})$, $NR^{5C}OR^{5A}$, $NR^{5C}R^{5D}$, $NR^{5C}(C(O)R^{5B})$, $NR^{5C}(C(O)OR^{5A})$, $N(OR^{5A})(C(O)R^{5B})$, $NR^{5C}(C(O)NR^{5C}R^{5D})$, $NR^{5C}(C(O)NR^{5C}(C(O)R^{5B}))$, $NR^{5C}(S(O)_2R^{5B})$, $NR^{5C}(S(O)_2NR^{5C}R^{5D})$, $NR^{5C}(C(O)NR^{5C}(S(O)_2R^{5B}))$, $OC(O)R^{5B}$, $OC(O)NR^{5C}R^{5D}$, $ONR^{5C}(C(O)R^{5B})$, $OS(O)_2R^{5B}$, $OP(O)(OR^{5E})(OR^{5F})$, $S(O)OR^{5A}$, $S(O)R^{5B}$, $S(O)_2R^{5B}$, $S(O)_2NR^{5C}R^{5D}$, $S(O)_2OR^{5A}$, $S(=NR^{5G})(O)R^{5B}$, $S(=NR^{5G})(O)NR^{5C}NR^{5D}$, $P(O)(OR^{5E})(OR^{5F})$, and $P(O)(OR^{5E})(R^{5F})$;

$R^{5'}$ is selected from H, C_{1-6}-alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6}-cycloalkyl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, phenyl, C_{3-6}-cycloalkyl-C_{1-3}-alkyl-, (4-10 membered heterocycloalkyl)-C_{1-3}-alkyl-, (5-10 membered heteroaryl)-C_{1-3}-alkyl-, phenyl-C_{1-3}-alkyl-, $C(O)OR^{5a'}$, $C(O)R^{5b'}$, $C(O)NR^{5c'}R^{5d'}$, $C(O)NR^{5c'}(OR^{5a'})$, $C(O)NR^{5c'}(S(O)_2R^{5b'})$, and $C(O)NR^{5c'}(S(O)_2NR^{5c'}R^{5d'})$, wherein the C_{1-6}-alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6}-cycloalkyl, and 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, phenyl, C_{3-6}-cycloalkyl-C_{1-3}-alkyl-, (4-10 membered heterocycloalkyl)-C_{1-3}-alkyl-, (5-10 membered heteroaryl)-C_{1-3}-alkyl-, and phenyl-C_{1-3}-alkyl- of $R^{5'}$ are each optionally substituted with 1, 2, or 3 groups independently selected from C_{1-3} alkyl, halo, CN, NO_2, $OR^{5A'}$, $SR^{5A'}$, $C(O)OR^{5A'}$, $C(O)R^{5B'}$, $C(O)NR^{5C'}R^{5D'}$, $C(O)NR^{5C'}(OR^{5A'})$, $C(O)NR^{5C'}(S(O)_2R^{5B'})$, $C(O)NR^{5C'}(S(O)_2NR^{5C'}R^{5D'})$, $NR^{5C'}OR^{5A'}$, $NR^{5C'}R^{5D'}$, $NR^{5C'}(C(O)R^{5B'})$, $NR^{5C'}(C(O)OR^{5A'})$,

$N(OR^{5A'})(C(O)R^{5B'})$, $NR^{5C'}(C(O)NR^{5C'}R^{5D'})$, $NR^{5C'}(C(O)NR^{5C'}(C(O)R^{5B'}))$, $NR^{5C'}(S(O)_2R^{5B'})$, $NR^{5C'}(S(O)_2NR^{5C'}R^{5D'})$, $NR^{5C'}(C(O)NR^{5C'}(S(O)_2R^{5B'}))$, $OC(O)R^{5B'}$, $OC(O)NR^{5C'}R^{5D'}$, $ONR^{5C'}(C(O)R^{5B'})$, $OS(O)_2R^{5B'}$, $OP(O)(OR^{5E'})(OR^{5F'})$, $S(O)OR^{5A'}$, $S(O)R^{5B'}$, $S(O)_2R^{5B'}$, $S(O)_2NR^{5C'}R^{5D'}$, $S(O)_2OR^{5A'}$, $S(=NR^{5G'})(O)R^{5B'}$, $S(=NR^{5G'})(O)NR^{5C'}NR^{5D'}$, $P(O)(OR^{5E'})(OR^{5F'})$, and $P(O)(OR^{5E'})(R^{5F'})$;

R^6 and $R^{6'}$ are each independently selected from (4-10 membered heterocycloalkyl)-C_{1-3}-alkyl- and (5-10 membered heteroaryl)-C_{1-3}-alkyl-, wherein the (4-10 membered heterocycloalkyl)-C_{1-3}-alkyl- and (5-10 membered heteroaryl)-C_{1-3}-alkyl- of R^6 and $R^{6'}$ are each optionally substituted with 1, 2, or 3 groups independently selected from C_{1-6}-alkyl, –OH, and halo;

R^{4a}, R^{4b}, R^{4c}, and R^{4d} are each independently selected from H, C_{1-6}-alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6}-cycloalkyl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, and phenyl, wherein the C_{1-6}-alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl of R^{4a}, R^{4b}, R^{4c}, and R^{4d} are each optionally substituted with 1, 2, or 3 groups independently selected from $C(O)OR^{4A}$, –OH and halo and the C_{3-6}-cycloalkyl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, and phenyl of R^{4a}, R^{4b}, R^{4c}, and R^{4d} are each optionally substituted with 1, 2, or 3 groups independently selected from C_{1-6}-alkyl, –OH, and halo;

R^{4e}, R^{4f}, and R^{4g} are each independently selected from H and C_{1-6}-alkyl;

R^{4A}, R^{4B}, R^{4C}, and R^{4D} are each independently selected from H, C_{1-6}alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6}-cycloalkyl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, and phenyl, wherein the C_{1-6}-alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl of R^{4A}, R^{4B}, R^{4C}, and R^{4D} are each optionally substituted with 1, 2, or 3 groups independently selected from –OH and halo and the C_{3-6}-cycloalkyl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, and phenyl of R^{4A}, R^{4B}, R^{4C}, and R^{4D} are each optionally substituted with 1, 2, or 3 groups independently selected from C_{1-6}-alkyl, –OH, and halo;

R^{4E}, R^{4F}, and R^{4G} are each independently selected from H and C_{1-6}-alkyl;

R^{5a}, R^{5b}, R^{5c}, and R^{5d} are each independently selected from H, C_{1-6}-alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6}-cycloalkyl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, and phenyl, wherein the C_{1-6}-alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl of R^{5a}, R^{5b}, R^{5c}, and R^{5d} are each optionally substituted with 1, 2, or 3 groups independently selected from –OH and halo and the C_{3-6}-cycloalkyl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, and phenyl of R^{5a}, R^{5b}, R^{5c}, and R^{5d} are each optionally substituted with 1, 2, or 3 groups independently selected from C_{1-6}-alkyl, –OH, and halo;

R^{5e}, R^{5f}, and R^{5g} are each independently selected from H and C_{1-6}-alkyl;

R^{5A}, R^{5B}, R^{5C}, and R^{5D} are each independently selected from H, C_{1-6}-alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6}-cycloalkyl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, and phenyl, wherein the C_{1-6}-alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl of R^{5A}, R^{5B}, R^{5C},

and R^{5D} are each optionally substituted with 1, 2, or 3 groups independently selected from –OH and halo and the C_{3-6}-cycloalkyl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, and phenyl of R^{5A}, R^{5B}, R^{5C}, and R^{5D} are each optionally substituted with 1, 2, or 3 groups independently selected from C_{1-6}-alkyl, –OH, and halo;

R^{5E}, R^{5F}, and R^{5G} are each independently selected from H and C_{1-6}-alkyl;


$R^{5a'}$, $R^{5b'}$, $R^{5c'}$, and $R^{5d'}$ are each independently selected from H, C_{1-6}-alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6}-cycloalkyl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, and phenyl, wherein the C_{1-6}-alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl of $R^{5a'}$, $R^{5b'}$, $R^{5c'}$, and $R^{5d'}$ are each optionally substituted with 1, 2, or 3 groups independently selected from –OH and halo and the C_{3-6}-cycloalkyl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, and phenyl of $R^{5a'}$, $R^{5b'}$, $R^{5c'}$, and $R^{5d'}$ are each optionally substituted with 1, 2, or 3 groups independently selected from C_{1-6}-alkyl, –OH, and halo;

$R^{5A'}$, $R^{5B'}$, $R^{5C'}$, and $R^{5D'}$ are independently selected from H, C_{1-6}-alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6}-cycloalkyl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, and phenyl, wherein the C_{1-6}-alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl of $R^{5A'}$, $R^{5B'}$, $R^{5C'}$, and $R^{5D'}$ are each optionally substituted with 1, 2, or 3 groups independently selected from –OH and halo and the C_{3-6}-cycloalkyl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, and phenyl of $R^{5A'}$, $R^{5B'}$, $R^{5C'}$, and $R^{5D'}$ are each optionally substituted with 1, 2, or 3 groups independently selected from C_{1-6}-alkyl, –OH, and halo; and

$R^{5E'}$, $R^{5F'}$, and $R^{5G'}$ are each independently selected from H and C_{1-6}-alkyl.

2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R^1 is chloro or fluoro; and R^2 is chloro or fluoro, and R^3 is $–CH_3$.

3. The compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein








.







4. The compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein R^4 is selected from C_{1-3}-alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{3-6}-cycloalkyl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, phenyl, $C(O)OR^{4a}$, and $C(O)NR^{4c}R^{4d}$, wherein the C_{1-3}-alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{3-6}-cycloalkyl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, and phenyl of R^4 are each




optionally substituted with 1, 2, or 3 groups independently selected from halo, C_{1-3}-alkyl, and $C(O)OR^{4A}$; wherein R^{4a}, R^{4c}, R^{4d} and R^{4A} are independently selected from H and C_{1-3}-alkyl.

5. The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein R^4 is selected from H, C_{1-3}-alkyl, C_{2-4} alkenyl, C_{3-6}-cycloalkyl, 5-10 membered heteroaryl and C(O)OH, wherein the C_{1-3}-alkyl, C_{2-4} alkenyl, C_{3-6}-cycloalkyl and 5-10 membered heteroaryl of R^4 are each optionally substituted with 1, 2, or 3 groups independently selected from halo and C(O)OH.





6. The compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein R^4 is selected from

, C(O)OH, CH_3, CF_3, , , , ,

, , , , , ,

, , and , or


wherein R^4 has the structure of:

, , , or .

7. The compound according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein R^5 is selected from C_{1-3}-alkyl, C_{2-4} alkenyl, C_{3-6}-cycloalkyl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, phenyl, halo, $C(O)OR^{5a}$, wherein the C_{1-3}-alkyl, C_{2-4} alkenyl, C_{3-6}-cycloalkyl, 4-10 membered heterocycloalkyl, 5-10 membered


heteroaryl, and phenyl are each optionally substituted with 1, 2, or 3 groups independently selected from halo, and $C(O)OR^{5A}$;
wherein R^{5a} is selected from H and C_{1-3}-alkyl; and R^{5A} is selected from H and C_{1-3}-alkyl.

8. The compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein R^5 is selected from H, C_{1-3}-alkyl, C_{2-4} alkenyl, C_{3-6}-cycloalkyl, and C(O)OH, wherein the C_{1-3}-alkyl, C_{2-4} alkenyl, and C_{3-6}-cycloalkyl of R^5 are each optionally substituted with 1, 2, or 3 groups independently selected from halo and C(O)OH, or
wherein R^5 is selected from








, and .

9. The compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, wherein R^5 is selected from




, $-CH_3$, C(O)OH, CF_3, F, $-CH_2CH_3$,


, 
, F, -CH_2CH_3, 
, 
, and 
.


10. The compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein R^6 and $R^{6'}$ are each independently selected from (4-6 membered heterocycloalkyl)-CH_2- and (5-6 membered heteroaryl)-CH_2-, wherein the (4-6 membered heterocycloalkyl)-CH_2- and (5-6 membered heteroaryl)-CH_2- of R^6 and $R^{6'}$ are each optionally substituted with 1, 2, or 3 groups independently selected from C_{1-6}-alkyl, –OH, and halo.

11. The compound according to any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, wherein R^6 and $R^{6'}$ are each independently selected from


, and


wherein  indicates the point of attachment to the rest of the molecule.

12. The compound according to any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, wherein R^6 and $R^{6'}$ are


,


wherein  indicates the point of attachment to the rest of the molecule.

13. The compound according to any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, which is a compound of formula (IIa):




(IIa),

14. The compound according to any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, which is a compound of formula (IIIa):






(IIIa),











15. The compound according to any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, which is a compound of formula (Va):

















(Va),

16. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, selected from
















,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

, and

or a pharmaceutically acceptable salt thereof.

17. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, selected from

(*E*)-3-(2-((4-((*S*)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[*d*][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((*S*)-oxetan-2-yl)methyl)-1H-imidazol-5-yl)acrylic acid;

(*E*)-3-(2-((4-((*S*)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[*d*][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((*S*)-oxetan-2-yl)methyl)-1H-imidazol-4-yl)acrylic acid;

2-((4-((*S*)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[*d*][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-4-methyl-1-(((*S*)-oxetan-2-yl)methyl)-1H-imidazole-5-carboxylic acid;

2-((4-((*S*)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[*d*][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-5-methyl-1-(((*S*)-oxetan-2-yl)methyl)-1H-imidazole-4-carboxylic acid;

(*E*)-3-(2-((4-((*S*)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[*d*][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-4-methyl-1-(((*S*)-oxetan-2-yl)methyl)-1H-imidazol-5-yl)acrylic acid;

(*E*)-3-(2-((4-((*S*)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-5-methyl-1-(((*S*)-oxetan-2-yl)methyl)-1H-imidazol-4-yl)acrylic acid;

2-((4-((*S*)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((*S*)-oxetan-2-yl)methyl)-4-(trifluoromethyl)-1H-imidazole-5-carboxylic;

(*E*)-3-(2-((4-((*S*)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((*S*)-oxetan-2-yl)methyl)-4-(trifluoromethyl)-1H-imidazol-5-yl)acrylic acid;

2-(2-((4-((*S*)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((*S*)-oxetan-2-yl)methyl)-4-(trifluoromethyl)-1H-imidazol-5-yl)cyclopropane-1-carboxylic acid;

3-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-4-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-5-yl)-1,2,4-oxadiazol-5(2H)-one;

3-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-5-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-4-yl)-1,2,4-oxadiazol-5(2H)-one;

4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)-1-((1-(((S)-oxetan-2-yl)methyl)-5-(1H-tetrazol-5-yl)-4-(trifluoromethyl)-1H-imidazol-2-yl)methyl)piperidine;

4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)-1-((1-(((S)-oxetan-2-yl)methyl)-4-(1H-tetrazol-5-yl)-5-(trifluoromethyl)-1H-imidazol-2-yl)methyl)piperidine;

3-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-4-(trifluoromethyl)-1H-imidazol-5-yl)-1,2,4-oxadiazol-5(2H)-one;

3-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-4-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-5-yl)propiolic acid;

3-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-4-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-5-yl)bicyclo[1.1.1]pentane-1-carboxylic acid;

3-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-5-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-4-yl)benzoic acid;

4-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-4-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-5-yl)benzoic acid;

5-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-5-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-4-yl)nicotinic acid;

(E)-3-(2-((4-(2-(4-chloro-2-fluorophenyl)-2-methyl-2,3-dihydrobenzofuran-7-yl)piperidin-1-yl)methyl)-4-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-5-yl)acrylic acid;

3-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-4-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-5-yl)propanoic acid;

(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-4-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazole-5-carbonyl)glycine;

3-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-5-yl)-2-methylpropanoic acid;

(E)-3-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-4-fluoro-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-5-yl)acrylic acid;

(E)-3-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-4-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-5-yl)-2-fluoroacrylic acid;

2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-4-ethyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazole-5-carboxylic acid;

3-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-4-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-5-yl)-3-hydroxypropanoic acid;

3-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-4-(4-fluorophenyl)-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-5-yl)propiolic acid;

3-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-5-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-4-yl)-5-fluorobenzoic acid;

5-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-5-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-4-yl)furan-2-carboxylic acid;

2-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-5-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-4-yl)oxazole-5-carboxylic acid;

5-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-5-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-4-yl)oxazole-2-carboxylic acid;

5-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-5-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-4-yl)-1,3,4-oxadiazole-2-carboxylic acid;

2-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-5-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-4-yl)oxazole-4-carboxylic acid;

5-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-5-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-4-yl)isoxazole-3-carboxylic acid;

3-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-5-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-4-yl)isoxazole-5-carboxylic acid;

4-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-5-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-4-yl)oxazole-2-carboxylic acid;

3-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-5-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-4-yl)-1-methyl-1H-pyrazole-5-carboxylic acid;

5-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-5-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-4-yl)-1-methyl-1H-pyrazole-3-carboxylic acid;

5-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-4-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-5-yl)nicotinic acid;

4-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-4-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-5-yl)thiazole-2-carboxylic acid;

2-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-4-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-5-yl)oxazole-4-carboxylic acid;

and

2-(2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-4-methyl-1-(((S)-oxetan-2-yl)methyl)-1H-imidazol-5-yl)oxazole-5-carboxylic acid.

or a pharmaceutically acceptable salt thereof.

18. A pharmaceutical composition comprising a compound according to any one of claims 1 to 17, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.

19. A combination comprising a compound according to any one of claims 1 to 17, or a pharmaceutically acceptable salt thereof, and one or more therapeutically active agents.

20. A compound according to any one of claims 1 to 17, or a pharmaceutically acceptable salt thereof, for use as a medicament.

21. A compound according to any one of claims 1 to 17, or a pharmaceutically acceptable salt thereof, for use in the treatment of a disorder or disease selected from obesity, type 2 diabetes mellitus, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, one or more diabetic complications, diabetic nephropathy, dyslipidemia, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), hypertension,

atherosclerosis, peripheral arterial disease, stroke, cardiomyopathy, atrial fibrillation, heart failure, coronary heart disease, and neuropathy.

22. Use of a compound according to any one of claims 1 to 17, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disorder or disease selected from obesity, type 2 diabetes mellitus, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, one or more diabetic complications, diabetic nephropathy, dyslipidemia, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), hypertension, atherosclerosis, peripheral arterial disease, stroke, cardiomyopathy, atrial fibrillation, heart failure, coronary heart disease, and neuropathy.

~~23. A method of agonizing GLP1R activity in a subject, wherein the method comprises administering to the subject a therapeutically effective amount of the compound according to any one of claims 1 to 17, or a pharmaceutically acceptable salt thereof.~~

~~24. A method of treating a disorder or disease selected from obesity, type 2 diabetes mellitus, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, one or more diabetic complications, diabetic nephropathy, dyslipidemia, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), hypertension, atherosclerosis, peripheral arterial disease, stroke, cardiomyopathy, atrial fibrillation, heart failure, coronary heart disease, and neuropathy in a subject, comprising administering to the subject a therapeutically effective amount of the compound according to any one of claims 1 to 17, or a pharmaceutically acceptable salt thereof.~~